Yeungnam Univ J Med.  2015 Jun;32(1):47-49. 10.12701/yujm.2015.32.1.47.

Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma

Affiliations
  • 1Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. cwkim@catholic.ac.kr

Abstract

Sorafenib is indicated for the treatment of advanced hepatocellular carcinoma (HCC), but although rare, tumor lysis syndrome (TLS) can be fatal in HCC patients with a large tumor burden. The authors describe the case of a 55-year-old hepatitis B carrier who visited our clinic with progressive dyspnea for 3 weeks. Chest and abdominal computed tomography revealed a huge HCC in the left lobe of the liver with invasion of the inferior vena cava, right atrium, and pulmonary arteries. After 8 days of sorafenib administration, TLS was diagnosed based on the characteristic findings of hyperuricemia, hyperkalemia, and acute kidney injury with massive tumor necrosis by follow-up imaging. Despite discontinuation of sorafenib and supportive care, the patient's clinical course rapidly deteriorated. The authors describe a rare but fatal complication that occurred soon after sorafenib initiation for HCC. Careful follow-up is required after commencing sorafenib therapy for the early diagnosis and management of TLS.

Keyword

Hepatocellular carcinoma; Sorafenib; Tumor lysis syndrome

MeSH Terms

Acute Kidney Injury
Carcinoma, Hepatocellular*
Dyspnea
Early Diagnosis
Follow-Up Studies
Heart Atria
Hepatitis B
Humans
Hyperkalemia
Hyperuricemia
Liver
Middle Aged
Necrosis
Pulmonary Artery
Thorax
Tumor Burden
Tumor Lysis Syndrome*
Vena Cava, Inferior
Full Text Links
  • YUJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr